Ascentage Pharma Group Inc. clinical trials

A country office of Ascentage Pharma Group International

The registry lists 53 studies whose lead sponsor is Ascentage Pharma Group Inc.. 31 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 15, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 53. List all 53 → · All Ascentage Pharma Group International studies →

• A Study of APG-3288 in Relapsed/Refractory Blood CancersRecruitingNCT07424833Phase 1

  Sponsor listed in the registry: Ascentage Pharma Group Inc.

• Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).RecruitingNCT06641414Phase 3

  Sponsor listed in the registry: Ascentage Pharma Group Inc.

• Study of Olverembatinib (HQP1351) in Patients With CML-CPRecruitingNCT06423911Phase 3

  Sponsor listed in the registry: Ascentage Pharma Group Inc.

• APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid TumorsRecruitingNCT05701306Phase 1/2

  Sponsor listed in the registry: Ascentage Pharma Group Inc.

• A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.RecruitingNCT06319456Phase 3

  Sponsor listed in the registry: Ascentage Pharma Group Inc.

• APG-2449 in Patients With Advanced Solid TumorsRecruitingNCT03917043Phase 1

  Sponsor listed in the registry: Ascentage Pharma Group Inc.

• A Study of Olverembatinib in SDH-deficient GIST.RecruitingNCT06640361Phase 3

  Sponsor listed in the registry: Ascentage Pharma Group Inc.

• APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced STRecruitingNCT06687070Phase 1

  Sponsor listed in the registry: Ascentage Pharma Group Inc.

• Global Trial in APG2575 for Patients With CLL/SLLRecruitingNCT06104566Phase 3

  Sponsor listed in the registry: Ascentage Pharma Group Inc.

• A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)RecruitingNCT06051409Phase 3

  Sponsor listed in the registry: Ascentage Pharma Group Inc.

• Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AMLRecruitingNCT04501120Phase 1/2

  Sponsor listed in the registry: Ascentage Pharma Group Inc.

• A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of APG-5918.RecruitingNCT05773586Phase 1

  Sponsor listed in the registry: Ascentage Pharma Group Inc.

• A Study of HQP1351 in Patients With GIST or Other Solid TumorsRecruitingNCT03594422Phase 1

  Sponsor listed in the registry: Ascentage Pharma Group Inc.

• Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLLRecruitingNCT05147467Phase 2

  Sponsor listed in the registry: Ascentage Pharma Group Inc.

• Pharmacokinetics of Olverembatinib in Participants With Hepatic ImpairmentRecruitingNCT07282093Phase 1

  Sponsor listed in the registry: Ascentage Pharma Group Inc.

• A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.RecruitingNCT06182969Phase 1/2

  Sponsor listed in the registry: Ascentage Pharma Group Inc.

• A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid LeukemiaRecruitingNCT06389292Phase 3

  Sponsor listed in the registry: Ascentage Pharma Group Inc.

• Study of HQP1351 in Subjects With Refractory CML and Ph+ ALLRecruitingNCT04260022Phase 1

  Sponsor listed in the registry: Ascentage Pharma Group Inc.

• A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHLRecruitingNCT04496349Phase 2

  Sponsor listed in the registry: Ascentage Pharma Group Inc.

• Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLLRecruitingNCT04494503Phase 1/2

  Sponsor listed in the registry: Ascentage Pharma Group Inc.

• Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLLRecruitingNCT04215809Phase 1

  Sponsor listed in the registry: Ascentage Pharma Group Inc.

• APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid TumorsRecruitingNCT04785196Phase 1/2

  Sponsor listed in the registry: Ascentage Pharma Group Inc.

• A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.RecruitingNCT04275518Phase 1

  Sponsor listed in the registry: Ascentage Pharma Group Inc.

• APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic MalignanciesRecruitingNCT03537482Early Phase 1

  Sponsor listed in the registry: Ascentage Pharma Group Inc.

• Named Patient Program for Olverembatinib (HQP1351)AvailableNCT05594758

  Sponsor listed in the registry: Ascentage Pharma Group Inc.

• A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDSRecruitingNCT04358393Phase 1/2

  Sponsor listed in the registry: Ascentage Pharma Group Inc.

• APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin LymphomaRecruitingNCT05186012Phase 1/2

  Sponsor listed in the registry: Ascentage Pharma Group Inc.

• APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple MyelomaRecruitingNCT04942067Phase 1/2

  Sponsor listed in the registry: Ascentage Pharma Group Inc.

• A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)RecruitingNCT04964518Phase 1/2

  Sponsor listed in the registry: Ascentage Pharma Group Inc.

• Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or LymphomasRecruitingNCT05415098Phase 1

  Sponsor listed in the registry: Ascentage Pharma Group Inc.

• A Clinical Study of APG-1387 in Combination With Entecavir in Patients With Chronic Hepatitis BRecruitingNCT04568265Phase 2

  Sponsor listed in the registry: Ascentage Pharma Group Inc.

• A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic MalignanciesActive, not recruitingNCT03913949Phase 1

  Sponsor listed in the registry: Ascentage Pharma Group Inc.

• Dose-escalation Study of APG-1387 and Toripalimab in Solid TumorsTerminatedNCT04284488Phase 1/2

  Sponsor listed in the registry: Ascentage Pharma Group Inc.

• APG-1387 Plus Chemotherapy in Advanced Pancreatic AdenocarcinomaTerminatedNCT04643405Phase 1/2

  Sponsor listed in the registry: Ascentage Pharma Group Inc.

• A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC PatientsActive, not recruitingNCT04001777Phase 1

  Sponsor listed in the registry: Ascentage Pharma Group Inc.

• APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström MacroglobulinemiaCompletedNCT04260217Phase 1

  Sponsor listed in the registry: Ascentage Pharma Group Inc.

• A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid TumorsActive, not recruitingNCT03611868Phase 1/2

  Sponsor listed in the registry: Ascentage Pharma Group Inc.

• A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine TumorsTerminatedNCT04893759Phase 1

  Sponsor listed in the registry: Ascentage Pharma Group Inc.

• A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic PhaseCompletedNCT04126681Phase 2

  Sponsor listed in the registry: Ascentage Pharma Group Inc.

• A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast CancerSuspendedNCT04946864Phase 1/2

  Sponsor listed in the registry: Ascentage Pharma Group Inc.

• The Absorption, Metabolism and Excretion of [14C]APG-2575 in Healthy SubjectsCompletedNCT05517616Phase 1

  Sponsor listed in the registry: Ascentage Pharma Group Inc.

• A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I MutationStatus unknownNCT03883100Phase 2

  Sponsor listed in the registry: Ascentage Pharma Group Inc.

• A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Chronic Phase With T315I MutationStatus unknownNCT03883087Phase 2

  Sponsor listed in the registry: Ascentage Pharma Group Inc.

• APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple MyelomaStatus unknownNCT04674514Phase 1/2

  Sponsor listed in the registry: Ascentage Pharma Group Inc.

• APG-1387 in Patients With Advanced Solid Tumors or Hematologic MalignanciesCompletedNCT03386526Phase 1

  Sponsor listed in the registry: Ascentage Pharma Group Inc.

• A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial TherapyWithdrawnNCT04354727Phase 1/2

  Sponsor listed in the registry: Ascentage Pharma Group Inc.

• Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung CancerTerminatedNCT04210037Phase 1/2

  Sponsor listed in the registry: Ascentage Pharma Group Inc.

• APG-115 in Patients With Advanced Solid Tumors or LymphomasCompletedNCT02935907Phase 1

  Sponsor listed in the registry: Ascentage Pharma Group Inc.

• A Study of APG-1252 in Patients With SCLC or Other Solid TumorsCompletedNCT03080311Phase 1

  Sponsor listed in the registry: Ascentage Pharma Group Inc.

• APG-1387 Study of Safety, Tolerability ,PK/PD in Patients With Chronic Hepatitis BCompletedNCT03585322Phase 1

  Sponsor listed in the registry: Ascentage Pharma Group Inc.